<DOC>
	<DOCNO>NCT00311480</DOCNO>
	<brief_summary>The present study aim evaluate safety immunogenicity two dos , administer three week apart , two influenza vaccine contain 7.5 microgram 15 microgram H5N1 influenza antigen , non-elderly adult elderly subject .</brief_summary>
	<brief_title>Safety Immunogenicity Two Doses , Administered Three Weeks Apart , Two ( Surface Antigen Adjuvanted With MF59C.1 ) Influenza Vaccines Non-Elderly Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Male female volunteer 18 year age old autoimmune disease serious acute , chronic progressive disease hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component vaccine . history neurological symptom sign , anaphylactic shock follow administration vaccine . within past 7 day , experience : acute disease , infection require systemic antibiotic antiviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>influenza</keyword>
	<keyword>pandemic influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>adjuvanted influenza vaccine</keyword>
</DOC>